Results 41 to 50 of about 14,077 (253)

TUMOR MARKERS СА 125 AND НЕ 4 AS PROGNOSTIC AND PREDICTIVE FACTORS IN BORDERLINE OVARIAN TUMORS

Сибирский онкологический журнал, 2016
The aim of the study was to evaluate the relationship between serum levels of tumor markers СА 125 and НЕ 4 and disease stage, histological type as well as treatment in patients with borderline ovarian tumors. Materials and methods.
A. N. Vasilyev, S. E. Krasilnikov, V. Е. Voitsitsky, A. V. Gerasimov, A. P. Kulidzhanyan, Е. V. Babayants, V. G. Sisakyan, М. I. Krylyshkin, N. A. Afanasyeva, A. S. Mansurova   +9 more
doaj  

Expression of selected epithelial–mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers

Tumor Biology, 2018
Epithelial ovarian neoplasms are a heterogeneous group including tumor subsets with distinct clinicopathologic and molecular features. Recent evidence from molecular and genomic studies suggests that whereas low-grade serous carcinomas and high-grade ...
Pawel Sadlecki, Jakub Jóźwicki, Paulina Antosik, Marek Grabiec   +3 more
doaj   +1 more source

Mutations in the KRAS gene in ovarian tumors.

Folia Histochemica et Cytobiologica, 2009
RAS genes are the most frequently mutated oncogenes detected in human cancer. In this study we analyzed the presence of mutations at codon 12 of the KRAS gene in 78 women with ovarian tumor, including 64 invasive ovarian cancers and 14 borderline ovarian
Wiesława Niklińska, Oksana Kowalczuk, Sławomir J Terlikowski, Bozena Dobrzycka, Lech Chyczewski, Marek Kulikowski   +5 more
doaj   +1 more source

Diagnosis of Ovarian Neoplasms Using Nomogram in Combination With Ultrasound Image-Based Radiomics Signature and Clinical Factors

Frontiers in Genetics, 2021
Objectives: To establish and validate a nomogram integrating radiomics signatures from ultrasound and clinical factors to discriminate between benign, borderline, and malignant serous ovarian tumors.Materials and methods: In this study, a total of 279 ...
Lisha Qi, Lisha Qi, Lisha Qi, Lisha Qi, Dandan Chen, Dandan Chen, Dandan Chen, Dandan Chen, Chunxiang Li, Chunxiang Li, Chunxiang Li, Chunxiang Li, Jinghan Li, Jingyi Wang, Jingyi Wang, Jingyi Wang, Jingyi Wang, Chao Zhang, Chao Zhang, Chao Zhang, Chao Zhang, Xiaofeng Li, Xiaofeng Li, Xiaofeng Li, Xiaofeng Li, Ge Qiao, Ge Qiao, Ge Qiao, Ge Qiao, Haixiao Wu, Haixiao Wu, Haixiao Wu, Haixiao Wu, Xiaofang Zhang, Wenjuan Ma, Wenjuan Ma, Wenjuan Ma, Wenjuan Ma   +37 more
doaj   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source

Clinico-Immunohistochemical Analysis of Ovarian Tumors in a South Indian Population: A Single-Center Study [PDF]

Journal of Clinical and Basic Research, 2022
Background and objectives: In India, ovarian tumors are the fifth leading cause of death in women. They account for 6% of all cancers in women. The present study aimed to provide support for a new theory of ovarian carcinogenesis by investigating the ...
Venkata Hari Charan Bagadi, Venkata Sunanda Lakshmi Gelli, Vijaya Lakshmi Muram Reddy, Krishna Murthy Badugu   +3 more
doaj  

Mucinous borderline ovarian tumor: a case report with diagnostic insights on ultrasound findings

Journal of Ultrasonography, 2016
Borderline ovarian tumors represent about 10% of all epithelial ovarian cancers, but in contrast to epithelial ovarian cancers, they constitute a group of tumors with a much better prognosis. An assessment of clinical presentation, physical examination,
Anna Szymańska-Dubowik, Marcin Śniadecki, Agnieszka Bianek-Bodzak, Marcin Liro, Edyta Szurowska   +4 more
doaj   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Recurrence of borderline ovarian tumors.

Experimental oncology, 2014
To increase the efficiency of diagnosis and treatment of patients with recurrences of borderline ovarian tumors (BOT).106 patients with BOT of stage I have been treated and clinically observed: the I group (82 patients, mean age -- 38.9 ± 5.5 years), who were treated with standard surgical operation (panhysterectomy); the II group (24 patients, mean ...
Svintsitskiy, V.S., Vorobyova, L.I., Klymenko, E.S., Dermenzhy, T.V., Tkalya, J.G.   +4 more
openaire   +2 more sources

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source